This supplement introduction discusses the controversy and rationale for maintaining β-blockers as a recommended initial therapy for hypertension.
β-Blockers have been used widely since the 1970s in the treatment of hypertension. In recent years, however, the use of β-blockers as an initial therapy in the treatment of hypertension has been challenged. The reasons for this controversy and the rationale for keeping β-blockers as a recommended treatment for hypertension are discussed in the articles in this supplement to the Canadian Journal of Cardiology (CJC).
No takes yet. Share an insight, caveat, or question.
Sheldon W. Tobe (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: